Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleophosmin 1 pseudogene 26 (NPM1P26) is a pseudogene—that is, a genomic DNA sequence similar to the NPM1 gene but typically non-functional and does not produce a functional protein product. Pseudogenes usually result from gene duplication or retrotransposition but lose coding capacity due to mutations. There is currently no evidence that NPM1P26 serves as a therapeutic target, is involved in human disease, or interacts with any drugs. Standard biological classification does not include NPM1P26 as a member of functionally-defined gene families such as receptors, enzymes, or transcription factors. There are no known utility, biomarker roles, or safety concerns associated with NPM1P26. This entry is not considered a canonical therapeutic target, and there does not appear to be significant published information or biomedical relevance associated with NPM1P26. If you are searching for the related protein-coding gene, you may be interested in “Nucleophosmin 1 (NPM1),” a nucleolar phosphoprotein with roles in ribosome biogenesis and cancer biology, which is entirely distinct from this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleophosmin 1 pseudogene 26 (NPM1P26).